Treatment outcomes for first localized, resectable recurrent retroperitoneal liposarcoma.

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

We will collect prospective data to see how different treatments work for adults with a first recurrent, resectable retroperitoneal well-differentiated or dedifferentiated liposarcoma.

Quick facts

• Study type: Observational
• Enrollment: 100 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Australia and New Zealand Sarcoma Association (Academic / other)
• Drugs / interventions: radiation, chemotherapy
• Locations: 9 sites (Atlanta, Georgia and 8 other locations)
• Trial ID: NCT07377747 on ClinicalTrials.gov

What this trial studies

This is a prospective observational study that captures diagnostic details, treatments, complications, survival, and patient-reported quality of life from hospital records and questionnaires over five years. Participants form a validation cohort for the TARPSWG recurrent retroperitoneal sarcoma nomogram. Treatment (surgery alone or preoperative radiotherapy with or without chemotherapy followed by surgery) is determined by the institutional multidisciplinary sarcoma team. Quality of life is collected using the EORTC QLQ-C30 and OLO-STO22 at multiple time points, with each questionnaire taking about 15–20 minutes.

Who should consider this trial

Good fit: Adults (≥18) with a first local recurrence of resectable retroperitoneal well-differentiated or dedifferentiated liposarcoma, no distant metastases on recent imaging, WHO performance status 0–2, ASA 1–3, and no prior radiotherapy to the retroperitoneum are ideal candidates.

Not a fit: Patients with distant metastatic disease, unresectable tumors, non-liposarcoma histology, prior retroperitoneal radiotherapy, or who are medically unfit for surgery are unlikely to benefit from enrollment.

Why it matters

Potential benefit: If successful, this could improve outcome prediction and help guide multidisciplinary decisions about surgery and radiotherapy for recurrent retroperitoneal liposarcoma.

How similar studies have performed: Retrospective cohorts and nomograms (including TARPSWG) have informed prognosis in retroperitoneal sarcoma, but prospective validation of these tools is relatively limited.

Eligibility criteria

Inclusion Criteria:

1. Adult age ≥ 18 presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection)
2. No distant metastasis on cross-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease
3. Previous histologically proven well-differentiated or dedifferentiated liposarcoma histology only
4. Sarcoma not originating from bone or abdominal or gynecological viscera
5. Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting)
6. WHO performance status 0-2
7. American Society of Anaesthesiologist (ASA) score 1-3
8. No prior RT for the retroperitoneal liposarcoma
9. Prior systemic therapy is allowed
10. No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease)
11. Women of childbearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment
12. Patient deemed able to comply with study requirements according to investigator evaluation
13. Signed, IRB-approved written informed consent

Exclusion Criteria:

1. Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team
2. Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible
3. Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease
4. Myxoid liposarcoma histology
5. Pregnancy

Where this trial is running

Atlanta, Georgia and 8 other locations

• Emory Winship Cancer Institute — Atlanta, Georgia, United States (Recruiting)
• OSU James Hospital — Columbus, Ohio, United States (Not_yet_recruiting)
• MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)
• Chris O'Brien Lifehouse — Camperdown, New South Wales, Australia (Recruiting)
• Prince of Wales Hospital — Randwick, New South Wales, Australia (Recruiting)
• Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia (Recruiting)
• UZ Leuven — Leuven, Flemish Brabant, Belgium (Recruiting)
• A.C.Camargo Cancer Center - Fundacao Antonio Prudente — Liberdade, São Paulo, Brazil (Recruiting)
• The Netherlands Cancer Institute — Amsterdam, North Holland, Netherlands (Recruiting)

Study contacts

• Principal investigator: Angela Hong — Chris O'Brien Lifehouse
• Study coordinator: Janina Chapman

Conditions Retroperitoneal Liposarcoma; Sarcoma; liposarcoma; retroperitoneal